YEZTUGO is the only PrEP option that can deliver 6 months of sustained HIV prevention at a time1,2

YEZTUGO (lenacapavir) innovation.

YEZTUGO is the only PrEP option that can deliver

6 months of sustained HIV prevention at a time1,2

After initiation dosing.

YEZTUGO is the
only PrEP option that can deliver

6 months of sustained HIV prevention at a time1,2

After initiation dosing.

YEZTUGO (lenacapavir) innovation.

JUMP TO:

Innovative study design
JUMP TO
  • Innovative study design
  • Drug depot
  • Novel MOA

    • Now you can offer individuals protection from HIV with subcutaneous (SC) administration every 6 months, and a flexible dosing window of 2 weeks before or after the 6-month scheduled injection date.1

    Clinically proven HIV prevention in populations with a high likelihood of acquiring HIV1-5

    Four individuals together representing YEZTUGO (lenacapavir) clinical trial participants. Actor portrayals.

    Actor portrayals.

    YEZTUGO was studied in the most age-, gender-, and racially inclusive PrEP clinical trials to date—including cisgender women, pregnant and lactating individuals, cisgender men, transgender and gender-diverse individuals, and adolescents aged ≥16 years—making YEZTUGO the twice-yearly PrEP option that many individuals have been waiting for.1-5,a

    The phase 3 clinical trials for YEZTUGO were the first to use background HIV (bHIV), an estimate of HIV incidence in the study population. To assess the efficacy of YEZTUGO, bHIV was used as a comparator in lieu of a placebo arm for ethical reasons.3,4

    aThe first phase 3 HIV prevention clinical trial to allow individuals to stay enrolled and continue on study drug if they became pregnant or started lactating.

    Replay

    Each injection forms a drug depot beneath the skin, contributing to its longer action1,3,4

    Replay

    After YEZTUGO is injected subcutaneously, it collects under the skin to form a drug depot. This drug depot is how YEZTUGO can be slowly released over time. Sometimes the drug depot may be felt as a bump/nodule, but may not be visible.

    Learn more about nodules here

    YEZTUGO is a first-in-class HIV-1 capsid inhibitor for PrEP3,4

    YEZTUGO is the first-and-only HIV prevention option that targets the HIV-1 capsid at multiple stages of the virus life cycle.1,3

    • The capsid core contains and protects viral RNA and enzymes for HIV replication6
    • The HIV-1 viral life cycle is dependent on the function of the capsid at the following stages of HIV-1 replication: nuclear transport, virus assembly and release, and capsid core formation1
    • YEZTUGO disrupts these stages in the HIV viral life cycle once HIV enters the body, resulting in an abnormal structure of the virus and, thus, inhibiting HIV-1 replication1
    Replay
    Replay

    Studied across the broadest range of individuals in 2 PrEP clinical trials1-5

    The PURPOSE 1 and PURPOSE 2 clinical trials together represent the most age-, gender-, and racially inclusive phase 3 PrEP clinical trials to date.

    Evaluate the study data

    The only twice-yearly dosing1,2

    The first-and-only HIV prevention option that is 2 subcutaneous injections every 6 months, done in office within a ±2-week continuation dosing window from the scheduled injection date.

    See dosing details

    MOA=mechanism of action; RNA=ribonucleic acid; SC=subcutaneous.

    References:
    1. YEZTUGO. Prescribing information. Gilead Sciences, Inc.; 2025.
    2. Full efficacy and safety results for Gilead investigational twice-yearly lenacapavir for HIV prevention presented at AIDS 2024. News release. Gilead Sciences, Inc.; July 24, 2024. Accessed January 6, 2025. https://www.gilead.com/news/news-details/2024/full-efficacy-and-safety-results-for-gilead-investigational-twice-yearly-lenacapavir-for-hiv-prevention-presented-at-aids-2024
    3. Bekker LG, Das M, Abdool Karim Q, et al; PURPOSE 1 study team. Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. N Engl J Med. 2024;391(13):1179-1192.
    4. Kelley CF, Acevedo-Quiñones M, Agwu AL, et al; PURPOSE 2 study team. Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons. N Engl J Med. 2025;392(13):1261-1276.
    5. Gallardo-Cartagena J, Phanuphak N, Ndlovu N, et al. Global racial, ethnic, and gender diversity among participants enrolled in the PURPOSE 2 trial of lenacapavir for pre-exposure prophylaxis. Paper presented at: 5th HIV Research for Prevention Conference (HIVR4P); October 6-10, 2024; Lima, Peru.
    6. Engelman A, Cherepanov P. The structural biology of HIV-1: mechanistic and therapeutic insights. Nat Rev Microbiol. 2012;10(4):279-290.
    This site is intended for US healthcare professionals
    Visit patient site Proceed to site
    You are leaving the
    YEZTUGO website
    Go back Go back